Mechanism of histone deacetylase inhibitor Trichostatin a induced apoptosis in human osteosarcoma cells

Apoptosis

Volumn 9, Issue 5, 2004, Pages 583-589

  Roh, M S ^a   Kim, C W ^b   Park, B S ^b   Kim, G C ^b   Jeong, J H ^a   Kwon, H C ^a   Suh, D J ^a   Cho, K H ^c   Yee, S B ^a   Yoo, Y H ^a  

^a Dong A University   (South Korea)

^b Pusan National University   (South Korea)

^c Inje University   (South Korea)

Author keywords

apoptosis; histone deacetylase; osteosarcoma; TSA

Indexed keywords

ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; CYTOCHROME C; GENISTEIN; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; MATRIX METALLOPROTEINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; TERT BUTYLOXYCARBONYL DEXTRO FLUOROMETHYL KETONE; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; CYTOSOL; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PLOIDY; PRIORITY JOURNAL;

APOPTOSIS; BONE NEOPLASMS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MEMBRANE POTENTIALS; MITOCHONDRIA; OSTEOSARCOMA;

EID: 4344689912     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:APPT.0000038037.68908.6e     Document Type: Article

References (31)

1. Lee DY, Hayes JJ, Pruss D, Wolffe AP. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 1993; 72: 73-84.
2. Wolffe AP, Guschin D. Chromatin structural features and targets that regulate transcription. J Struct Biol 2000; 129: 102-122.
3. Weidle UH, Grossmann A. Inhibition of histone deacetylases: A new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res 2000; 20: 1127-1132.
4. Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell 2002; 108: 475-487.
5. Loidl P, Grobner P. Postsynthetic acetylation of histones during the cell cycle: A general function for the displacement of histones during chromatin rearrangements. Nucleic Acids Res 1987; 15: 8351-8366.
6. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001; 13: 477-483.
7. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: Induces of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92: 1210-1216.
8. Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop 2002; 397: 40-52.
9. Bruland OS, Phil A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 1997; 33: 1725-1731.
10. Sowa Y, Orita T, Minamikawa S, et al. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 1997; 241: 142-150.
11. Hirose T, Sowa Y, Takahashi S, et al. p53-independent induction of Gadd45 by histone deacetylase inhibitor: Coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene 2003; 22: 7762-7773.
12. Marks PA, Rifkind RA. Erythroleukemic differentiation. Annu Rev Biochem 1978; 47: 419-448.
13. Hoshikawa Y, Kwon HJ, Yoshida M, Horinouchi S, Beppu T. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res 1994; 214: 189-197.
14. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 1996; 5: 245-253.
15. Saito A, Yamashita T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999; 96: 4592-4597.
16. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437-443.
17. Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 2002; 97: 290-296.
18. Deroanne CF, Bonjean K, Servotte S, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002; 21: 427-436.
19. Stossi F, Barnett DH, Frasor J, Komm B, Lyttle CR, Katzenellenbogen BS. Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor {alpha} or estrogen receptor {beta} in human osteosarcoma cells: Distinct and common target genes for these receptors. Endocrinology 2004; [Epub ahead of print].
20. Park BS, Baek SJ, Song KH, et al. Genistein-induced apoptosis of p815 mastocytoma cells is mediated by Bax and augmented by a proteasome inhibitor, lactacystin. Nutr Cancer 2002; 42: 248-255.
21. Farhan H, Cross HS. Transcriptional inhibition of CYP24 by genistein. Ann NY Acad Sci 2002; 973: 459-462.
22. Morabito N, Crisafulli A, Vergara C, et al. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: A randomized double-blind placebo-controlled study. J Bone Miner Res 2002; 17: 1904-1912.
23. ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 1995; 92: 6289-6293.
24. Liggett WH Jr, Sewell DA, Rocco J, et al. p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res 1996; 56: 4119-4123.
25. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000.
26. Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17: 5001-5014.
27. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725-734.
28. Richon VM, Webb Y, Merger R, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996; 93: 5705-5708.
29. Xiao H, Hasegawa T, Isobe K. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J Cell Biochem 1999; 73: 291-302.
30. DiGiuseppe JA, Weng LJ, Yu KH, et al. Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: Structure-function analysis. Leukemia 1999; 13: 1243-1253.
31. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000; 97: 10014-10019.